- Home
- KALV vs AMAL Comparison
KALV vs AMAL Comparison
Compare KALV & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- AMAL
- Stock Information
- Founded
- KALV N/A
- AMAL 1923
- Country
- KALV United States
- AMAL United States
- Employees
- KALV N/A
- AMAL N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- AMAL Commercial Banks
- Sector
- KALV Health Care
- AMAL Finance
- Exchange
- KALV Nasdaq
- AMAL Nasdaq
- Market Cap
- KALV 796.4M
- AMAL 760.6M
- IPO Year
- KALV N/A
- AMAL 2018
- Fundamental
- Price
- KALV $11.10
- AMAL $26.21
- Analyst Decision
- KALV Strong Buy
- AMAL Hold
- Analyst Count
- KALV 8
- AMAL 2
- Target Price
- KALV $26.43
- AMAL $33.00
- AVG Volume (30 Days)
- KALV 1.5M
- AMAL 159.5K
- Earning Date
- KALV 12-04-2025
- AMAL 10-23-2025
- Dividend Yield
- KALV N/A
- AMAL 2.18%
- EPS Growth
- KALV N/A
- AMAL 3.73
- EPS
- KALV N/A
- AMAL 3.34
- Revenue
- KALV $1,426,000.00
- AMAL $304,724,000.00
- Revenue This Year
- KALV N/A
- AMAL $9.82
- Revenue Next Year
- KALV $209.38
- AMAL $11.11
- P/E Ratio
- KALV N/A
- AMAL $7.70
- Revenue Growth
- KALV N/A
- AMAL 4.35
- 52 Week Low
- KALV $7.30
- AMAL $25.03
- 52 Week High
- KALV $17.28
- AMAL $38.19
- Technical
- Relative Strength Index (RSI)
- KALV 38.98
- AMAL 41.88
- Support Level
- KALV $10.75
- AMAL $25.13
- Resistance Level
- KALV $12.23
- AMAL $27.79
- Average True Range (ATR)
- KALV 0.62
- AMAL 0.70
- MACD
- KALV -0.01
- AMAL -0.07
- Stochastic Oscillator
- KALV 23.41
- AMAL 39.83
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.